Suraj Kalia
Stock Analyst at Oppenheimer
(3.81)
# 654
Out of 5,173 analysts
91
Total ratings
46.15%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $26.02 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $112.08 | +56.14% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $227.08 | +32.11% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $29.78 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $104.85 | +25.89% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $69.54 | +43.80% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $52.16 | +235.51% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $10.82 | +66.36% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $82.02 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $20.93 | +5.11% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $118.14 | +1.57% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $35.72 | -10.41% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $107.86 | -13.78% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.92 | +155.10% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.15 | +312.70% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $85.33 | +58.21% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $227.97 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $26.51 | +13.16% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.81 | +24,658.60% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $71.65 | +35.38% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $19.17 | +46.06% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $4.19 | +7.40% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.85 | +1,781.69% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $478.04 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.44 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $16.61 | +502.05% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $65.94 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $26.02
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $112.08
Upside: +56.14%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $227.08
Upside: +32.11%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $29.78
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $104.85
Upside: +25.89%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $69.54
Upside: +43.80%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $52.16
Upside: +235.51%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $10.82
Upside: +66.36%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $82.02
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $20.93
Upside: +5.11%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $118.14
Upside: +1.57%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $35.72
Upside: -10.41%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $107.86
Upside: -13.78%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $3.92
Upside: +155.10%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.15
Upside: +312.70%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $85.33
Upside: +58.21%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $227.97
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $26.51
Upside: +13.16%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.81
Upside: +24,658.60%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $71.65
Upside: +35.38%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $19.17
Upside: +46.06%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $4.19
Upside: +7.40%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $0.85
Upside: +1,781.69%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $478.04
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.44
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $16.61
Upside: +502.05%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $65.94
Upside: -